Sugi Predict

Sugi Predict / Compounds / SCHEMBL10188488

SCHEMBL10188488

SCHEMBL10188488

O=C(O)c1[nH]ccc(=O)c1OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.64
▸ NSD2 O96028 1/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ PPARG P37231 1/20 0.48
▸ RIN1 Q13671 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ NCOR2 Q9Y618 1/20 0.48
▸ LMNA P02545 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ USP2 O75604 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ NR4A2 P43354 2/20 0.44
▸ NR4A1 P22736 1/20 0.44
▸ NR4A3 Q92570 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HPGD P15428 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21274657 0.88 POLB (0.61) POLBNSD2ABL1PPARGRIN1
SCHEMBL21259220 0.86 POLB (0.62) POLBNSD2ABL1PPARGRIN1
SCHEMBL10188493 0.85 POLB (0.60) POLBNSD2ABL1PPARGRIN1
SCHEMBL19588885 0.83 POLB (0.58) POLBNSD2ABL1PPARGRIN1
SCHEMBL10188498 0.81 POLB (0.52) POLBGAAALDH1A1TSHRMEN1
SCHEMBL23748321 0.80 POLB (0.51) POLBNSD2ABL1PPARGRIN1
SCHEMBL21185145 0.79 POLB (0.50) POLBNSD2ABL1PPARGRIN1
SCHEMBL24893628 0.79 ALDH1A1 (0.53) POLBL3MBTL1LMNAGAAALDH1A1
SCHEMBL23748282 0.79 POLB (0.53) POLBNSD2ABL1PPARGRIN1
SCHEMBL82673 0.78 POLB (1.00) POLBNSD2ABL1PPARGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176807-A Alpha-hydroxy ketone nitrogen-containing fused ring compound and application thereof 北京英飞智药科技有限公司 2024-12-24 — — CN disclosed
US-11807648-B2 Process for preparing substituted polycyclic pyridone derivative and crystal thereof SHIONOGI & CO., LTD. (JP) 2023-11-07 — — US disclosed
US-11807648-B2 Process for preparing substituted polycyclic pyridone derivative and crystal thereof SHIONOGI & CO., LTD. (JP) 2023-11-07 — — US disclosed
EP-4194459-A1 PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND CRYSTAL THEREOF Shionogi & Co., Ltd (JP) 2023-06-14 — — EP disclosed
WO-2023018913-A1 POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA MERCK SHARP & DOHME LLC (US) 2023-02-16 — — WO disclosed
US-20230040262-A1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2023-02-09 — — US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 — — US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 — — US disclosed
EP-3752144-B1 TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-12-28 — — EP disclosed
EP-3752144-B1 TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-12-28 — — EP disclosed
US-8865907-B2 Method of producing pyrone and pyridone derivatives SHIONOGI & CO., LTD. (JP) 2014-10-21 — — US disclosed
US-20130197219-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO., LTD. (JP) 2013-08-01 — — US disclosed
EP-2620436-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG Shionogi&Co., Ltd. (JP) 2013-07-31 — — EP disclosed
US-20120184734-A1 SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2012-07-19 — — US disclosed
US-20120184734-A1 SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2012-07-19 — — US disclosed
EP-2444400-A1 SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE Shionogi&Co., Ltd. (JP) 2012-04-25 — — EP disclosed
US-20120022251-A1 METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2012-01-26 — — US disclosed
WO-2010147068-A1 SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE 塩野義製薬株式会社 (JP) 2010-12-23 — — WO disclosed
CN-100448873-C Cycloalkyl derivatives of 3-hydroxy-4-pyridones APOTEX INC (CA) 2009-01-07 — — CN disclosed
CN-1926135-A Cycloalkyl derivatives of 3-hydroxy-4-pyridones APOTEX INC (CA) 2007-03-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 POLB 74/4885NSD2 1126/4885ABL1 1174/4885
US-11807648-B2 Process for preparing substituted polycyclic pyridone derivative and crystal thereof REN, C5, PDXK POLB 1891/4885NSD2 1535/4885ABL1 1784/4885
US-20230040262-A1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES RNGTT, CPSF6, RNASEL POLB 83/4885NSD2 2324/4885ABL1 4735/4885
US-20120022251-A1 METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES PNPO, PDXK, CYP3A5 POLB 1394/4885NSD2 3175/4885ABL1 1306/4885
US-20120184734-A1 SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE CNBP, ZC3HAV1, DPP4 POLB 309/4885NSD2 840/4885ABL1 3911/4885
US-20130197219-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG PREP, UNG, DPP4 POLB 292/4885NSD2 1602/4885ABL1 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.